REG - Surgical Innovations - CE mark certification obtained for CELLIS range

Surgical InnovationsAnnouncement

13/09/2018 07:05

RNS Number : 6175A
Surgical Innovations Group PLC
13 September 2018
 


 
 
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
 
 
Surgical Innovations Group plc
("SI Group" or the "Company")
 
CE mark certification obtained for CELLIS range
 
Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, provides a further update relating to the CELLIS range of products supplied to its UK distribution business, Elemental Healthcare Limited ("Elemental") by Meccellis Biotech SA ("Meccellis").
 
On 12 September 2018, Elemental received confirmation from Meccellis that CE certification has been issued in respect of the full range of CELLIS products previously sold by Elemental, and also covering innovative new products including the CELLIS Breast Pocket range launched at the London Breast meeting on 6 & 7 September 2018. The certificates are valid until August 2023.
 
Meccellis are now in a position to resume manufacture of these products, and detailed plans are in progress to facilitate a timely and controlled reintroduction to the UK market in coming weeks.
 
 
For further information please contact:
 



Surgical Innovations Group Plc


www.sigroupplc.com




Nigel Rogers, Executive Chairman


Tel: 0113 230 7597




Melanie Ross, COO and CFO


 




 


 




WH Ireland Limited (NOMAD & Broker)


Tel: 0113 394 6600




Tim Feather


 




Chris Viggor


 




 


 




Walbrook PR (Financial PR & Investor Relations)


Tel: 020 7933 8780 or si@walbrookpr.com




Paul McManus


Mob: 07980 541 893




Lianne Cawthorne


Mob: 07584 391 303



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEAPNAFLDPEFF